Abstract
There are two Main goals in the treatment of acquired FVIII-inhibitors: first, to control acute bleeding episodes and second, to induce immune tolerance (IT). For the induction of IT Mainly immunosuppressive drugs are given (e.g. corticosteroids, cyclophosphamide). As part of the »malmö treatment protocol« (MTP) and its Modifications they are combined with immunoadsorptions (IA), intravenous immunoglobulins (IVIG) and the causative antigen, i.e. FVIII. The application of FVIII in huge doses for immune Modulation is associated with very high costs and therefore there is still an important question: Is a FVIII substitution really Mandatory?
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Geisen, U., Grossmann, R., Mansouri-Taleghani, B., Schambeck, C.M., Böck, M., Walter, U. (2003). Treatment of FVIII-Autoantibodies by Protein A-based Immunoadsorption and Immunosuppression: A Regimen without FVIII Substitution. In: Scharrer, I., Schramm, W. (eds) 32nd Hemophilia Symposium. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18150-4_32
Download citation
DOI: https://doi.org/10.1007/978-3-642-18150-4_32
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-43884-7
Online ISBN: 978-3-642-18150-4
eBook Packages: Springer Book Archive